Four promoters of IRF5 respond distinctly to stimuli and are affected by autoimmune-risk polymorphisms

Frontiers in Immunology

Volumn 4, Issue NOV, 2013, Pages

  Clark, Daniel N ^a   Read R Daniel, D ^a   Mayhew, Vera ^a   Petersen, Stephen C ^a   Argueta, Lissenya B ^a   Stutz, Lance A ^a   Till, Rodney E ^a   Bergsten, Sean M ^a   Robinson, Brandon S ^a   Baumann, Douglas G ^a   Casey Heap, J ^a   Poole, Brian D ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

Alternative promoters; Autoimmune disease risk; Interferon; IRF5; Systemic lupus erythematosus

Indexed keywords

BETA GLUCURONIDASE; CHEMOKINE RECEPTOR CCR7; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 6; LUCIFERASE; PROTEIN NOXA; PROTEIN P53; TOLL LIKE RECEPTOR 7;

ARTICLE; CGGGG INDEL; CONTROLLED STUDY; DNA LIBRARY; DNA SEQUENCE; EPSTEIN BARR VIRUS INFECTION; EXON; GENOTYPING TECHNIQUE; HUMAN; HUMAN CELL; INDEL MUTATION; LIGATION; LUCIFERASE ASSAY; LUMINESCENCE; MULTIPLE SCLEROSIS; PLASMID; POLYMERASE CHAIN REACTION SYSTEM; PROMOTER REGION; RECEPTOR GENE; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84890341801     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00360     Document Type: Article

References (68)

1. Kimura K, Wakamatsu A, Suzuki Y, Ota T, Nishikawa T, Yamashita R, et al. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome Res (2006) 16(1):55-65. doi:10.1101/gr.4039406
2. Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem (2004) 279(43):45194-207. doi:10.1074/jbc.M400726200
3. Lien C, Fang CM, Huso D, Livak F, Lu R, Pitha PM. Critical role of IRF-5 in regulation of B-cell differentiation. Proc Natl Acad Sci U S A (2010) 107(10):4664-8. doi:10.1073/pnas.0911193107
4. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al. IRF5 promotes inflammatory macrophage polarization and T(H)1-T(H)17 responses. Nat Immunol (2011) 12(3):231-8. doi:10.1038/ni.1990
5. Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res (2003) 63(19):6424-31.
6. Alonso-Perez E, Suarez-Gestal M, Calaza M, Kwan T, Majewski J, Gomez-Reino JJ, et al. Cis-regulation of IRF5 expression is unable to fully account for systemic lupus erythematosus association: analysis of multiple experiments with lymphoblastoid cell lines. Arthritis Res Ther (2011) 13(3):R80. doi:10.1186/ar3343
7. Stephens RM, Schneider TD. Features of spliceosome evolution and function inferred from an analysis of the information at human splice sites. J Mol Biol (1992) 228(4):1124-36. doi:10.1016/0022-2836(92)90320-J
8. Kawasaki A, Kyogoku C, Ohashi J, Miyashita R, Hikami K, Kusaoi M, et al. Association of IRF5 polymorphisms with systemic lupus erythematosus in a Japanese population: support for a crucial role of intron 1 polymorphisms. Arthritis Rheum (2008) 58(3):826-34. doi:10.1002/art.23216
9. Brogna S, Wen J. Nonsense-mediated mRNA decay (NMD) mechanisms. Nat Struct Mol Biol (2009) 16(2):107-13. doi:10.1038/nsmb.1550
10. Sigurdsson S, Nordmark G, Göring HH, Lindroos K, Wiman AC, Sturfelt G, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet (2005) 76(3):528-37. doi:10.1086/428480
11. Kozyrev SV, Lewén S, Reddy PM, Pons-Estel B; Argentine Collaborative Group, Witte T, et al. Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus. Arthritis Rheum (2007) 56(4):1234-41. doi:10.1002/art.22497
12. Kelly JA, Kelley JM, Kaufman KM, Kilpatrick J, Bruner GR, Merrill JT, et al. Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes Immun (2008) 9(3):187-94. doi:10.1038/gene.2008.4
13. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet (2006) 38(5):550-5. doi:10.1038/ng1782
14. Dieguez-Gonzalez R, Calaza M, Perez-Pampin E, de la Serna AR, Fernandez-Gutierrez B, Castañeda S, et al. Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. Arthritis Rheum (2008) 58(5):1264-74. doi:10.1002/art.23426
15. Sigurdsson S, Padyukov L, Kurreeman FA, Liljedahl U, Wiman AC, Alfredsson L, et al. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum (2007) 56(7):2202-10. doi:10.1002/art.22704
16. Dieudé P, Guedj M, Wipff J, Avouac J, Fajardy I, Diot E, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis. Arthritis Rheum (2009) 60(1):225-33. doi:10.1002/art.24183
17. Kristjansdottir G, Sandling JK, Bonetti A, Roos IM, Milani L, Wang C, et al. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet (2008) 45(6):362-9. doi:10.1136/jmg.2007.055012
18. Dideberg V, Kristjansdottir G, Milani L, Libioulle C, Sigurdsson S, Louis E, et al. An insertion-deletion polymorphism in the interferon regulatory factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet (2007) 16(24):3008-16. doi:10.1093/hmg/ddm259
19. Miceli-Richard C, Comets E, Loiseau P, Puechal X, Hachulla E, Mariette X. Association of an IRF5 gene functional polymorphism with Sjogren's syndrome. Arthritis Rheum (2007) 56(12):3989-94. doi:10.1002/art.23142
20. Feng D, Stone RC, Eloranta ML, Sangster-Guity N, Nordmark G, Sigurdsson S, et al. Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum (2010) 62(2):562-73. doi:10.1002/art.27223
21. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. Association of the IRF5 risk haplotype with high serum interferon-α activity in systemic lupus erythematosus patients. Arthritis Rheum (2008) 58(8):2481-7. doi:10.1002/art.23613
22. Hedl M, Abraham C. IRF5 risk polymorphisms contribute to interindividual variance in pattern recognition receptor-mediated cytokine secretion in human monocyte-derived cells. J Immunol (2012) 188(11):5348-56. doi:10.4049/jimmunol.1103319
23. Sigurdsson S, Göring HH, Kristjansdottir G, Milani L, Nordmark G, Sandling JK, et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet (2008) 17(6):872-81. doi:10.1093/hmg/ddm359
24. Nordmark G, Kristjansdottir G, Theander E, Eriksson P, Brun JG, Wang C, et al. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjogren's syndrome. Genes Immun (2008) 10(1):68-76. doi:10.1038/gene.2008.94
25. Fan JH, Gao LB, Pan XM, Li C, Liang WB, Liu J, et al. Association between IRF-5 polymorphisms and risk of acute coronary syndrome. DNA Cell Biol (2010) 29(1):19-23. doi:10.1089/dna.2009.0929
26. Mancl ME, Hu G, Sangster-Guity N, Olshalsky SL, Hoops K, Fitzgerald-Bocarsly P, et al. Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function. J Biol Chem (2005) 280(22):21078-90. doi:10.1074/jbc.M500543200
27. Niewold TB, Clark DN, Salloum R, Poole BD. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol (2010) 2010:8. doi:10.1155/2010/948364
28. Yanai H, Chen HM, Inuzuka T, Kondo S, Mak TW, Takaoka A, et al. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc Natl Acad Sci U S A (2007) 104(9):3402-7. doi:10.1073/pnas.0611559104
29. Guthridge JM, Clark DN, Templeton A, Dominguez N, Lu R, Vidal GS, et al. Effects of IRF5 lupus risk haplotype on pathways predicted to influence B cell functions. J Biomed Biotechnol (2012) 2012:594056. doi:10.1155/2012/594056
30. Poole BD, Scofield RH, Harley JB, James JA. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity (2006) 39(1):63-70. doi:10.1080/08916930500484849
31. Poole BD, Templeton AK, Guthridge JM, Brown EJ, Harley JB, James JA. Aberrant Epstein-Barr viral infection in systemic lupus erythematosus. Autoimmun Rev (2009) 8(4):337-42. doi:10.1016/j.autrev.2008.12.008
32. James JA, Robertson JM. Lupus and Epstein-Barr. Curr Opin Rheumatol (2012) 24(4):383-8. doi:10.1097/BOR.0b013e3283535801
33. Martin HJ, Lee JM, Walls D, Hayward SD. Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus. J Virol (2007) 81(18):9748-58. doi:10.1128/JVI.01122-07
34. Gelfand Y, Rodriguez A, Benson G. TRDB-the tandem repeats database. Nucleic Acids Res (2007) 35(Database issue):D80-7. doi:10.1093/nar/gkl1013
35. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet (1992) 1(1):45-9. doi:10.1038/ng0492-45
36. Lee TH, Maheshri N. A regulatory role for repeated decoy transcription factor binding sites in target gene expression. Mol Syst Biol (2012) 8:576. doi:10.1038/msb.2012.7
37. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 2(1):a001008. doi:10.1101/cshperspect.a001008
38. Vesuna F, Winnard P Jr, Raman V. Enhanced green fluorescent protein as an alternative control reporter to Renilla luciferase. Anal Biochem (2005) 342(2):345-7. doi:10.1016/j.ab.2005.04.047
39. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A (2004) 101(16):6062-7. doi:10.1073/pnas.0400782101
40. Di Domizio J, Blum A, Gallagher-Gambarelli M, Molens JP, Chaperot L, Plumas J. TLR7 stimulation in human plasmacytoid dendritic cells leads to the induction of early IFN-inducible genes in the absence of type I IFN. Blood (2009) 114(9):1794-802. doi:10.1182/blood-2009-04-216770
41. Bao M, Liu YJ. Regulation of TLR7/9 signaling in plasmacytoid dendritic cells. Protein Cell (2013) 4(1):40-52. doi:10.1007/s13238-012-2104-8
42. Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med (2009) 206(9):1983-94. doi:10.1084/jem.20090480
43. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer (2001) 1(1):68-76. doi:10.1038/35094077
44. Horvath MM, Wang X, Resnick MA, Bell DA. Divergent evolution of human p53 binding sites: cell cycle versus apoptosis. PLoS Genet (2007) 3(7):e127. doi:10.1371/journal.pgen.0030127
45. Liu HY, Hong YF, Huang CM, Chen CY, Huang TN, Hsueh YP. TLR7 negatively regulates dendrite outgrowth through the Myd88-c-Fos-IL-6 pathway. J Neurosci (2013) 33(28):11479-93. doi:10.1523/JNEUROSCI.5566-12.2013
46. Weber A, Zimmermann C, Mausberg AK, Kieseier BC, Hartung HP, Hofstetter HH. Induction of pro-inflammatory cytokine production in thymocytes by the immune response modifiers Imiquimod and Gardiquimod™. Int Immunopharmacol (2013) 17(2):427-31. doi:10.1016/j.intimp.2013.06.023
47. Hu G, Barnes BJ. IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway. J Biol Chem (2009) 284(5):2767-77. doi:10.1074/jbc.M804744200
48. Londin ER, Keller MA, D'Andrea MR, Delgrosso K, Ertel A, Surrey S, et al. Whole-exome sequencing of DNA from peripheral blood mononuclear cells (PBMC) and EBV-transformed lymphocytes from the same donor. BMC Genomics (2011) 12:464. doi:10.1186/1471-2164-12-464
49. Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM, et al. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res (2012) 41(Database issue):D56-63. doi:10.1093/nar/gks1172
50. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci (2004) 117(Pt 25):5965-73. doi:10.1242/jcs.01589
51. de Alboran IM, O'Hagan RC, Gärtner F, Malynn B, Davidson L, Rickert R, et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity (2001) 14(1):45-55. doi:10.1016/S1074-7613(01)00088-7
52. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D'Andrea A, et al. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature (1996) 383(6598):344-7. doi:10.1038/383344a0
53. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett (2003) 85(2):85-95. doi:10.1016/S0165-2478(02)00228-6
54. Phillips JE, Corces VG. CTCF: master weaver of the genome. Cell (2009) 137(7):1194-211. doi:10.1016/j.cell.2009.06.001
55. Mori T, Anazawa Y, Iiizumi M, Fukuda S, Nakamura Y, Arakawa H. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene (2002) 21(18):2914. doi:10.1038/sj.onc.1205459
56. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer (1998) 34(10):1514-21. doi:10.1016/S0959-8049(98)00228-7
57. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer (2003) 3(5):330-8. doi:10.1038/nrc1074
58. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol (2010) 11(9):621-32. doi:10.1038/nrm2952
59. Li M, He Y, Dubois W, Wu X, Shi J, Huang J. Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. Mol Cell (2012) 46(1):30-42. doi:10.1016/j.molcel.2012.01.020
60. Mellor J. The dynamics of chromatin remodeling at promoters. Mol Cell (2005) 19(2):147-57. doi:10.1016/j.molcel.2005.06.023
61. Hu G, Mancl ME, Barnes BJ. Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. Cancer Res (2005) 65(16):7403-12. doi:10.1158/0008-5472.CAN-05-0583
62. Valouev A, Johnson SM, Boyd SD, Smith CL, Fire AZ, Sidow A. Determinants of nucleosome organization in primary human cells. Nature (2011) 474(7352):516-20. doi:10.1038/nature10002
63. Kuroyanagi H, Watanabe Y, Hagiwara M. CELF family RNA-binding protein UNC-75 regulates two sets of mutually exclusive exons of the unc-32 gene in neuron-specific manners in Caenorhabditis elegans. PLoS Genet (2013) 9(2):e1003337. doi:10.1371/journal.pgen.1003337
64. Chen W, Lam SS, Srinath H, Jiang Z, Correia JJ, Schiffer CA, et al. Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5. Nat Struct Mol Biol (2008) 15(11):1213-20. doi:10.1038/nsmb.1496
65. Barash Y, Calarco JA, Gao W, Pan Q, Wang X, Shai O, et al. Deciphering the splicing code. Nature (2010) 465(7294):53-9. doi:10.1038/nature09000
66. Zubovic L, Baralle M, Baralle FE. Mutually exclusive splicing regulates the Nav 1.6 sodium channel function through a combinatorial mechanism that involves three distinct splicing regulatory elements and their ligands. Nucleic Acids Res (2012) 40(13):6255-69. doi:10.1093/nar/gks249
67. Batteux F, Palmer P, Daëron M, Weill B, Lebon P. FCgammaRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus. Eur Cytokine Netw (1999) 10(4):509-14.
68. Ning S, Huye LE, Pagano JS. Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit. J Virol (2005) 79(18):11671-6. doi:10.1128/JVI.79.18.11671-11676.2005